Want to see ABVC full AI Analyst Report?
Top Page
ABVC BioPharma
(NASDAQ:ABVC)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.00
▲(16.28% Upside)
Action:Reiterated
Date:09/16/26
The score is primarily held down by weak financial performance marked by negative/unstable revenue, sizable ongoing losses, and continued cash burn, despite improved leverage. Technicals are mixed with only short-term support but a longer-term downtrend. Valuation is not supportive because losses make P/E less meaningful and there is no dividend yield.
Positive Factors
Improved leverage
Leverage has improved materially, reducing balance-sheet pressure and providing greater flexibility for development spending. Although losses remain substantial, the current debt burden is comparatively modest, making financing and capital allocation less constrained than in 2024.
Negative Factors
Deep operating losses
The company has not established profitable operations, with negative reported revenue and large net and operating losses. Persistent losses weaken earnings quality, erode shareholder value, and increase dependence on successful pipeline advancement or external financing to sustain the business.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved leverage
Leverage has improved materially, reducing balance-sheet pressure and providing greater flexibility for development spending. Although losses remain substantial, the current debt burden is comparatively modest, making financing and capital allocation less constrained than in 2024.
Read all positive factors
ABVC BioPharma (ABVC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$35.83M
Dividend YieldN/A
Average Volume (3M)116.47K
Price to Earnings (P/E)―
Beta (1Y)1.72
Revenue Growth-100.00%
EPS Growth-55.90%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.29
Shares Outstanding31,154,755
10 Day Avg. Volume134,286
30 Day Avg. Volume116,474
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)4.46
Price to Sales (P/S)0.00
P/FCF Ratio-16.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.3
Revenue Forecast (FY)$35.28M
ABVC BioPharma Business Overview & Revenue Model
Company Description
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key c...
How the Company Makes Money
ABVC’s revenue model is primarily based on monetizing its drug-development pipeline rather than selling established commercial products. The company seeks to generate income through (1) out-licensing and collaboration agreements, where third parti...
ABVC BioPharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -795.95K | 0.00 | 509.59K | 152.43K | 969.78K | 355.80K |
| Gross Profit | -795.95K | 0.00 | 508.83K | -149.61K | 683.37K | 350.71K |
| EBITDA | -7.83M | -7.43M | -4.34M | -6.33M | -15.20M | -10.97M |
| Net Income | -7.90M | -7.91M | -4.90M | -7.79M | -16.42M | -12.84M |
Balance Sheet | ||||||
| Total Assets | 19.40M | 21.06M | 7.54M | 7.78M | 10.93M | 13.70M |
| Cash, Cash Equivalents and Short-Term Investments | 94.36K | 745.83K | 928.55K | 796.09K | 1.47M | 5.94M |
| Total Debt | 1.76M | 3.47M | 3.20M | 2.77M | 3.41M | 3.34M |
| Total Liabilities | 7.13M | 7.76M | 6.82M | 6.53M | 6.34M | 4.83M |
| Stockholders Equity | 10.29M | 11.11M | 1.23M | 1.55M | 4.45M | 8.84M |
Cash Flow | ||||||
| Free Cash Flow | -2.45M | -2.99M | -1.81M | -4.21M | -7.52M | -7.62M |
| Operating Cash Flow | -2.69M | -2.99M | -1.81M | -4.19M | -7.40M | -7.60M |
| Investing Cash Flow | -597.42K | -1.21M | 0.00 | -360.19K | -1.72M | -805.97K |
| Financing Cash Flow | 2.17M | 4.64M | 1.98M | 3.87M | 4.01M | 10.00M |
ABVC BioPharma Technical Analysis
Neutral
0.86
Price Trends
1.03
Positive
1.17
Negative
1.44
Negative
Market Momentum
0.03
Negative
62.94
Neutral
84.18
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVC, the sentiment is Neutral. The current price of 0.86 is below the 20-day moving average (MA) of 0.94, below the 50-day MA of 1.03, and below the 200-day MA of 1.44, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 62.94 is Neutral, neither overbought nor oversold. The STOCH value of 84.18 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ABVC.
ABVC BioPharma Risk Analysis
ABVC BioPharma disclosed 48 risk factors in its most recent earnings report. ABVC BioPharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Cybersecurity incidents and decentralization of documents may hurt the company's business, damage its reputation, increase its costs, and cause losses. Q4, 2023
ABVC BioPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $252.90M | -1.90 | -314.08% | ― | 40.21% | 13.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $59.76M | -5.04 | 83.45% | ― | ― | 15.65% | |
48 Neutral | $21.10M | -0.39 | -618.87% | ― | ― | 73.74% | |
46 Neutral | $38.55M | -0.76 | -156.02% | ― | -95.74% | -23.18% | |
44 Neutral | $61.72M | -5.21 | -144.31% | ― | -26.89% | 56.50% | |
42 Neutral | $35.83M | -3.93 | -71.47% | ― | -100.00% | -55.90% |
* Healthcare Sector Average
ABVC
ABVC BioPharma
1.16
-1.68
-59.15%
CRVO
CervoMed
2.43
-5.36
-68.81%
HYFT
MindWalk Holdings
1.36
-0.37
-21.39%
JSPR
Jasper Therapeutics
0.62
-1.88
-75.32%
INKT
MiNK Therapeutics
12.05
-3.04
-20.15%
CAMP
CAMP4 Therapeutics Corporation
4.24
1.96
85.96%
ABVC BioPharma Corporate Events
Business Operations and StrategyDividendsM&A Transactions
ABVC BioPharma Completes BioKey Cayman Spin-Off Transaction
Neutral
Aug 27, 2026
On August 21, 2026, ABVC BioPharma completed the legal and structural separation of its subsidiary, BioKey (Cayman), Inc., distributing roughly 15% of BioKey Cayman’s ordinary shares to ABVC common stockholders as a pro rata dividend. Shareh...
Business Operations and StrategyDividendsRegulatory Filings and Compliance
ABVC BioPharma Delays Planned BioKey Share Distribution
Neutral
Aug 4, 2026
On August 3, 2026, ABVC BioPharma postponed the planned distribution of ordinary shares of its subsidiary BioKey (Cayman), Inc., which had been scheduled for that same date. The move is intended to give the company more time to complete administra...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.